POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.

@article{Kupitz2015POORLO,
  title={POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.},
  author={Elke H Kupitz and Tjebo F. C. Heeren and Frank G. Holz and Peter Charbel Issa},
  journal={Retina},
  year={2015},
  volume={35 12},
  pages={
          2619-26
        }
}
PURPOSE To investigate long-term effects after intravitreal inhibition of vascular endothelial growth factor in nonproliferative macular telangiectasia type 2. METHODS Nine patients with macular telangiectasia type 2 treated with 12 monthly intravitreal ranibizumab injections in 1 eye were investigated again after a mean follow-up of 6.0 ± 0.4 years. Functional assessment included best-corrected visual acuity and microperimetry testing. Morphologic investigations included optical coherence… CONTINUE READING
BETA
2
Twitter Mentions

Similar Papers